TOKYO, March 13, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboration agreement (the "Collaboration") ...
This study presents valuable findings that could potentially allow a deeper understanding of the immunopathogenesis underlying influenza infection in aged mice. The results are based on solid evidence ...
I have always been a bit of a skeptic about how important AI will be for the biotechnology industry, but, given a few […] ...
InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...
In sum, the nonapeptide Oxytocin presents as a structurally well-defined peptide with a receptor system that is widely ...
AI protein function prediction uses machine learning models trained on sequence and structural data to infer protein roles at ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
News-Medical.Net on MSN
Biomimetic platform enhances CAR T therapy for relapsed and refractory leukemia
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric antigen receptor on the surface of the patient's T ...
An electronic nose modeled on insect antennae simultaneously identifies gas mixtures and pinpoints their three-dimensional ...
Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically engineering a chimeric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results